Britain and America have signed a key commercial pact that will keep no tariffs on British medicine products being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the NHS. This pledge secures that import taxes on these vital products will remain at zero for a period of three years.
This deal comes after earlier threats to hike duties on branded drug imports, with potential rates floated reaching double the cost.
"This deal with the Britain reinforces the international landscape for innovative medicines and brings long-overdue fairness to U.S.–U.K. medicine commerce," a statement said.
Commercial Impact
Drugs represent one of the the United Kingdom's largest exports to the United States, which is clearly the largest buyer for large British pharmaceutical firms.
Statistics reveal that in the 12 months leading up to September, the UK exported medicines totaling billions to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This deal protects jobs, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Key British Pledges
The pact includes several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a target to increase total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be restricted at 15%. In the past, refunds were more than 20%.
Industry Background
The pact follows a long-running tension between the sector and the UK government over spending levels and regulatory access.
The disagreement were heightened by arguments that US consumers were charged a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or abandoned, while major expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
